CZ165693A3 - 5-heteroindole derivatives, process of their preparation, intermediates of such process and the use of these compounds - Google Patents

5-heteroindole derivatives, process of their preparation, intermediates of such process and the use of these compounds Download PDF

Info

Publication number
CZ165693A3
CZ165693A3 CS931656A CS165693A CZ165693A3 CZ 165693 A3 CZ165693 A3 CZ 165693A3 CS 931656 A CS931656 A CS 931656A CS 165693 A CS165693 A CS 165693A CZ 165693 A3 CZ165693 A3 CZ 165693A3
Authority
CZ
Czechia
Prior art keywords
group
compound
indol
formula
hydrogen
Prior art date
Application number
CS931656A
Other languages
Czech (cs)
English (en)
Inventor
Jolanta T Nowakowski
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CZ165693A3 publication Critical patent/CZ165693A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Luminescent Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CS931656A 1991-02-12 1992-02-03 5-heteroindole derivatives, process of their preparation, intermediates of such process and the use of these compounds CZ165693A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65471291A 1991-02-12 1991-02-12
PCT/US1992/000556 WO1992013856A1 (en) 1991-02-12 1992-02-03 5-heteroyl indole derivatives

Publications (1)

Publication Number Publication Date
CZ165693A3 true CZ165693A3 (en) 1994-05-18

Family

ID=24625959

Family Applications (1)

Application Number Title Priority Date Filing Date
CS931656A CZ165693A3 (en) 1991-02-12 1992-02-03 5-heteroindole derivatives, process of their preparation, intermediates of such process and the use of these compounds

Country Status (24)

Country Link
EP (1) EP0571471B1 (enExample)
JP (1) JPH07121942B2 (enExample)
KR (1) KR930703305A (enExample)
AT (1) ATE135005T1 (enExample)
AU (1) AU655456B2 (enExample)
CA (1) CA2101521A1 (enExample)
CZ (1) CZ165693A3 (enExample)
DE (1) DE69208868T2 (enExample)
DK (1) DK0571471T3 (enExample)
ES (1) ES2084347T3 (enExample)
FI (1) FI933551L (enExample)
GR (1) GR3019778T3 (enExample)
HU (1) HUT65766A (enExample)
IE (1) IE920442A1 (enExample)
IL (1) IL100888A0 (enExample)
MX (1) MX9200569A (enExample)
MY (1) MY131298A (enExample)
NO (1) NO932859L (enExample)
NZ (1) NZ241584A (enExample)
PT (1) PT100114A (enExample)
TW (1) TW263508B (enExample)
WO (1) WO1992013856A1 (enExample)
YU (1) YU13792A (enExample)
ZA (1) ZA92969B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW288010B (enExample) * 1992-03-05 1996-10-11 Pfizer
PL172405B1 (en) * 1992-04-07 1997-09-30 Pfizer Derivatives of indole
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
GB9226537D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
GB9226532D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
ES2070087B1 (es) * 1993-08-13 1996-02-16 Pfizer Derivados de indol
US5468768A (en) * 1994-01-06 1995-11-21 Bristol-Myers Squibb Company Antimigraine derivatives of indolylcycloalkanylamines
US6423731B2 (en) 1994-01-06 2002-07-23 Zeneca Limited Indole derivatives as prodrugs of 5-HT1-like receptor agonists
CA2190501A1 (en) * 1994-05-19 1995-11-30 Jose Luis Castro Pineiro Piperazine, piperidine and tetrahydropyridine derivatives of indol-3-ylalkyl as 5-ht1d-alpha agonists
AU2621995A (en) * 1994-06-01 1995-12-21 Zeneca Limited Indole derivatives as prodrugs of 5-ht1-like receptor agonists
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
GB9501865D0 (en) * 1995-01-31 1995-03-22 Merck Sharp & Dohme Therapeutic agents
CZ288897A3 (cs) * 1995-03-20 1998-02-18 Eli Lilly And Company V poloze 5-substituovaný 3-(1,2,3,6-tetrahydropyridin-4-yl)indol a 3-(piperidin-4-yl)indol a farmaceutický prostředek, který je obsahuje
AU7261196A (en) * 1995-10-10 1997-04-30 Eli Lilly And Company N-{2-substituted-3-(2-aminoethyl)-1h-indol-5-yl}-amides: new 5-ht1f agonists
GB9523583D0 (en) * 1995-11-17 1996-01-17 Merck Sharp & Dohme Therapeutic agents
FR2754709B1 (fr) 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
FR2763243A1 (fr) * 1997-05-14 1998-11-20 Pf Medicament Utilisation d'amines indoliques comme medicaments antithrombotiques
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
EP1068198B1 (en) 1998-03-09 2003-05-28 H.Lundbeck A/S 5-heteroaryl substituted indoles
AU4831899A (en) * 1998-06-30 2000-01-17 Eli Lilly And Company 5-HT1F agonists
MXPA01010655A (es) * 1999-04-21 2002-11-04 Allelix Biopharma Compuestos de piperidin-indol que tienen afinidad por 5-ht6.
WO2001034146A1 (en) * 1999-11-08 2001-05-17 Smithkline Beecham Corporation Novel anti-infectives
BR0114552A (pt) * 2000-10-20 2003-07-01 Biovitrum Ab N1- (benzenosulfonil) indóis 2-,3-,4-, 5- substituìdos e seu uso em terapia
DE10121217A1 (de) 2001-04-30 2002-10-31 Merck Patent Gmbh 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden
WO2003099206A2 (en) 2002-05-21 2003-12-04 Bristol-Myers Squibb Company Indole compounds useful as impdh inhibitors
CA2509982C (en) * 2002-11-28 2011-11-08 Suven Life Sciences Limited N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
WO2005005439A1 (en) * 2003-07-09 2005-01-20 Suven Life Sciences Limited Benzothiazino indoles
US20050245540A1 (en) * 2003-12-09 2005-11-03 Fujisawa Pharmaceutical Co., Ltd. New methods
WO2005121132A1 (ja) * 2004-06-11 2005-12-22 Shionogi & Co., Ltd. 抗ｈｃｖ作用を有する縮合ヘテロ環化合物
SI1883451T1 (sl) 2005-04-13 2011-04-29 Neuraxon Inc Substituirane indolne spojine z NOS inhibitorno aktivnostjo
UA97348C2 (en) * 2005-07-29 2012-02-10 4Сц Аг HETEROCYCLIC NF-kB INHIBITORS
CA2637531A1 (en) * 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
AR060451A1 (es) 2006-04-13 2008-06-18 Neuraxon Inc Compuestos de indol 1,5 y 3,6-sustituidos con actividad inhibitoria de nos
WO2008021851A2 (en) * 2006-08-09 2008-02-21 Smithkline Beecham Corporation Novel compounds as antagonists or inverse agonists for opioid receptors
TW200848021A (en) 2007-03-06 2008-12-16 Wyeth Corp Sulfonylated heterocycles useful for modulation of the progesterone receptor
US8673909B2 (en) 2007-11-16 2014-03-18 Neuraxon, Inc. Indole compounds and methods for treating visceral pain
EP2638014B1 (en) 2010-11-08 2017-01-04 Lycera Corporation N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of ror-gamma activity and the treatment of diseases
AU2013259624B2 (en) 2012-05-08 2017-10-19 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
JP6236068B2 (ja) 2012-05-08 2017-11-22 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＲＯＲγ活性を阻害し疾患を治療するためのテトラヒドロナフチリジンおよび関連二環式化合物
US9783511B2 (en) 2013-12-20 2017-10-10 Lycera Corporation Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
WO2015095788A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
US9809561B2 (en) 2013-12-20 2017-11-07 Merck Sharp & Dohme Corp. Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
MX2016010998A (es) 2014-02-27 2017-03-31 Lycera Corp Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados.
US10189777B2 (en) 2014-05-05 2019-01-29 Lycera Corporation Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease
JP6728061B2 (ja) 2014-05-05 2020-07-22 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγアゴニストとして用いるテトラヒドロキノリンスルホンアミド及び関連化合物ならびに疾患の治療
JP2018510135A (ja) 2015-02-11 2018-04-12 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＲＯＲγＴ阻害剤としての置換ピラゾール化合物及びその使用
EP3292119A4 (en) 2015-05-05 2018-10-03 Lycera Corporation DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
CA2987289A1 (en) 2015-06-11 2016-12-15 Lycera Corporation Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
KR20180070697A (ko) 2015-10-27 2018-06-26 머크 샤프 앤드 돔 코포레이션 Ror감마t 저해제로서의 치환된 인다졸 화합물 및 이의 용도
WO2017075178A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
EP3368535B1 (en) 2015-10-27 2020-12-02 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8332437D0 (en) * 1983-12-06 1984-01-11 Glaxo Group Ltd Chemical compounds
DE3678805D1 (de) * 1985-11-08 1991-05-23 Glaxo Group Ltd Indolderivate.
GB8600398D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
EG19650A (en) * 1990-06-07 1995-09-30 Wellcome Found Derivatives of indol and their use for treatment of megraine

Also Published As

Publication number Publication date
DK0571471T3 (da) 1996-04-01
HUT65766A (en) 1994-07-28
EP0571471A1 (en) 1993-12-01
ZA92969B (en) 1993-08-11
ES2084347T3 (es) 1996-05-01
NZ241584A (en) 1994-12-22
JPH06500122A (ja) 1994-01-06
ATE135005T1 (de) 1996-03-15
WO1992013856A1 (en) 1992-08-20
FI933551A7 (fi) 1993-08-11
FI933551A0 (fi) 1993-08-11
AU655456B2 (en) 1994-12-22
EP0571471B1 (en) 1996-03-06
MY131298A (en) 2007-08-30
MX9200569A (es) 1992-08-01
NO932859D0 (no) 1993-08-11
PT100114A (pt) 1993-05-31
NO932859L (no) 1993-08-11
IE920442A1 (en) 1992-08-12
TW263508B (enExample) 1995-11-21
FI933551L (fi) 1993-08-11
DE69208868D1 (de) 1996-04-11
IL100888A0 (en) 1992-11-15
AU1263792A (en) 1992-09-07
KR930703305A (ko) 1993-11-29
JPH07121942B2 (ja) 1995-12-25
GR3019778T3 (en) 1996-07-31
CA2101521A1 (en) 1992-08-13
HU9302328D0 (en) 1993-10-28
YU13792A (sh) 1994-11-15
DE69208868T2 (de) 1996-10-17

Similar Documents

Publication Publication Date Title
CZ165693A3 (en) 5-heteroindole derivatives, process of their preparation, intermediates of such process and the use of these compounds
US5409941A (en) 5-heteroyl indole derivatives
CN1122032C (zh) 用于治疗心血管疾病的新的取代吡唑衍生物
CN1187330C (zh) 吲哚衍生物、制备它们的方法、含有它们的药用组合物和它们的医疗应用
CN1165537C (zh) 作为5-ht2c兴奋剂的吡咯并吲哚、吡啶并吲哚和氮杂�并吲哚
CA2169179C (en) 5-arylindole derivatives
AU671836B2 (en) Fused imidazole and triazole derivatives as 5-HT1 receptor agonists
CZ283001B6 (cs) 5-Arylindolové deriváty, meziprodukty pro jejich výrobu a famaceutické prostředky na jejich bázi
EP0773942A1 (en) 4-indole derivatives as serotonin agonists and antagonists
BG60402B2 (bg) Заместени бициклични съединения
JP2010532748A (ja) カルシウムチャネル遮断薬としての２−置換インドール誘導体
SK105294A3 (en) Indole derivatives, method of their preparation, intermediates of this process, pharmaceutical agents containing these derivatives and use of these derivatives
CN102224154A (zh) 作为EP4受体拮抗剂的β-咔啉磺酰脲衍生物
CS85692A3 (en) 6-HETEROCYCLO-4-AMINO-1,3,4,5-TETRAHYDROBENZO(cd)INDOLE
CA1337202C (en) Cyclic amides which are leukotriene antagonists
EP0227241A2 (en) Medicinal indole and indazole keto sulphone derivatives
US5607957A (en) Imidazole, triazole and tetrazole derivatives
US5510359A (en) Heteroaromatic 5-hydroxytryptamine receptor agonists
JPH0378854B2 (enExample)
AU673098B2 (en) Antimigraine cyclobutenedione derivatives of indolylalkyl-pyridinyl and pyrimidinylpiperazines
US5521188A (en) Antimigraine cyclobutenedione derivatives of indolylalkyl-pyridinyl and pyrimidinylpiperazines
FR2761070A1 (fr) Derives de dihydropyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique
US5047402A (en) Cyclic amides as medicaments
HK1024243A (en) Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
HK1023119B (en) Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases